ATS 2019 Virtual Final Program

9:50 Break 10:00 Hypersensitivity Pneumonitis: What and Where Is the Antigen; Strategies for Diagnosis and Treatment? M. Vasakova, MD, PhD, Prague, Czech Republic 10:20 Connective Tissue Disease ILD: Role of Serology in Diagnosis and Role of Immune Modulating Agents for Treatment A. Fischer, MD, Denver, CO 10:40 Lymphatics in ILD and Beyond M. Itkin, MD, Philadelphia, United States 11:00 Multidisciplinary Discussions for an Accurate Diagnosis L.A. Ho, MD, Seattle, WA 12:30 LUNCH 1:30 Lessons from ILD Registries K.R. Flaherty, MD, Ann Arbor, MI 1:50 Biomarkers in ILD: What Do They Mean and Are They Clinically Relevant? E.S. White, MD, MS, ATSF, Ann Arbor, MI 2:10 Sarcoidosis: Getting to the Heart of the Matter M.A. Judson, MD, Albany, NY 2:30 Genetics of Interstitial Lung Disease: IPF and Beyond, What to Tell Your Patients and Their Family Members N. Kaminski, MD, ATSF, New Haven, CT 2:50 Break 3:00 Reducing Symptoms and Improving Quality of Life for Patients with Fibrotic Lung Disease K.O. Lindell, PhD, RN, ATSF, Pittsburgh, PA 3:20 Stem Cell Therapy for Fibrotic Lung Disease: Still a Concept While Patients Can Receive “Stem Cell Treatment” Elsewhere? M.K. Glassberg Csete, MD, Miami, FL 3:40 Idiopathic Pulmonary Fibrosis: Landscape of Current and Novel Treatment in the Horizon L. Richeldi, MD, PhD, Rome, Italy This session and the International Conference are supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. CLINICAL POSTGRADUATE COURSE CME Credits Available: 7 PG7 ADVANCING CARE OF SICKLE CELL LUNG DISEASE: A PRACTICAL GUIDE TO PATIENT MANAGEMENT R Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 : Registrants must bring a laptop to the course to view the course material. Assemblies on Pediatrics; Clinical Problems; Pulmonary Circulation; Sleep and Respiratory Neurobiology 8:00 a.m. - 4:00 p.m. KBHCCD Room C156 (Level 1) Target Audience Pediatric and adult pulmonary fellows, clinicians and researchers interested in an up-to-date review of the pulmonary complications of sickle cell disease across the lifespan, highlighting evaluation and management of these conditions Objectives At the conclusion of this session, the participant will be able to: • evaluate and manage cardiopulmonary abnormalities in patients with SCD across the lifespan to improve patient health and quality of life; • understand the clinical burden of pulmonary complications of SCD and approaches to management of those complications in low-resource settings; • employ strategies to implement comprehensive pulmonary care programs for adult and pediatric patients with SCD. Pulmonary disease is among the most common causes of accelerated mortality in individuals with sickle cell disease (SCD). This course provides an overview of the pathophysiology and clinical spectrum of cardiopulmonary complications of SCD across the lifespan. Course faculty, international experts in sickle cell lung disease, will present a state of the art review of acute and chronic pulmonary complications of SCD that addresses underlying pathophysiology and considerations for management in low-resource areas. The format includes lectures with audience participation via the Audience Response System, question and answer periods, case discussions, and a panel discussion on establishing a multidisciplinary sickle cell pulmonary program. Chairing: R.T. Cohen, MD, MPH, Boston, MA A.P. Ruhl, MD, MHS, Bethesda, MD S.C. Sadreameli, MD, MHS, Baltimore, MD E.S. Klings, MD, Boston, MA 8:00 Introduction R.T. Cohen, MD, MPH, Boston, MA 8:10 Sickle Cell Disease 101 for the Pulmonologist A. Campbell, MD, Washington, DC 8:35 Acute Chest Syndrome Management and New Directions A.P. Ruhl, MD, MHS, Bethesda, MD 9:00 Transgenic Mouse Models to Study Sickle Cell Lung Disease S. Ofori-Acquah, PhD, Pittsbuurgh, PA 9:25 Cases from the Clinic: Understanding Pulmonary Function in SCD R.T. Cohen, MD, MPH, Boston, MA 9:50 Question and Answer Period #1 10:00 Break 10:10 All That Wheezes Is Not Asthma in SCD B. Kopp, MD, Columbus, OH 10:35 Impact of the Indoor and Outdoor Environment on Pulmonary Outcomes in SCD S.C. Sadreameli, MD, MHS, Baltimore, MD ATS 2019 • Dallas, TX 6 FRIDAY • MAY 17